BiotechTube

DSXS1411 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Plaque Psoriasis

Conditions

Plaque Psoriasis

Trial Timeline

Apr 1, 2015 → Jan 29, 2016

NCT ID
NCT02413229

About DSXS1411 + Placebo

DSXS1411 + Placebo is a phase 2 stage product being developed by Sun Pharmaceutical for Plaque Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT02413229. Target conditions include Plaque Psoriasis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02413229Phase 2Completed

Competing Products

20 competing products in Plaque Psoriasis

See all competitors
ProductCompanyStageHype Score
CT-P17 + EU-approved HumiraCelltrionPhase 3
77
CT-P55 + EU-approved CosentyxCelltrionPhase 3
77
alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
85
alefaceptAstellas PharmaPhase 3
77
Amevive exposureAstellas PharmaPre-clinical
23
alefacept + placeboAstellas PharmaPhase 3
77
alefaceptAstellas PharmaApproved
85
alefaceptAstellas PharmaApproved
85
AlefaceptAstellas PharmaApproved
85
Halobetasol PropionateSun PharmaceuticalPhase 2
52
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)Sun PharmaceuticalPhase 2
52
DSXS + PlaceboSun PharmaceuticalPhase 3
77
DSXSSun PharmaceuticalPhase 2
52
DSXS topicalSun PharmaceuticalPhase 2
52
Halobetasol Topical LotionSun PharmaceuticalApproved
85
Tildrakizumab 200 mg + Tildrakizumab 100 mg + Matching PlaceboSun PharmaceuticalPhase 3
77
Tildrakizumab + PlaceboSun PharmaceuticalPhase 3
77
Tildrakizumab 200 mg + Tildrakizumab 100 mg + Tildrakizumab Placebo + Etanercept Placebo + Etanercept 50 mgSun PharmaceuticalPhase 3
77
MK-3222 200 mg + MK-3222 100 mg + Placebo to MK-3222 + Placebo to Etanercept + Etanercept 50 mgSun PharmaceuticalPhase 3
77
Topical TA-102 A + Topical TA-102 B + Topical TA-102 C + Topical TA-102 D + Topical TA-102 ESun PharmaceuticalPhase 1
33

Other Products from Sun Pharmaceutical

Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85